Cover Image

Urticaria multiforme following nivolumab-ipilimumab therapy

Saved in:

Bibliographic Details
Main Authors:	Sonal Muzumdar (Author), Reid Waldman (Author), Jun Lu (Author)
Format:	Book
Published:	Wolters Kluwer, 2020-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022)

Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma
by: Andrey Moiseyenko, et al.
Published: (2020)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
by: Jason Zhang, et al.
Published: (2019)

Herpes zoster following axillary botulinum toxin for hyperhidrosis
by: Sonal Muzumdar, et al.
Published: (2020)

A case of ruptured Baker's cyst induced by nivolumab and ipilimumab
by: Marie Kubo, et al.
Published: (2023)

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
by: Yuri Sakaguchi, et al.
Published: (2020)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
by: Kinjal Sanghavi, et al.
Published: (2020)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
by: Yi Yang, et al.
Published: (2020)

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult
by: Courtney M. Kenyon, BS, et al.
Published: (2024)

Pediatric model‐based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma
by: Shengnan Du, et al.
Published: (2024)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
by: Pramod Savarapu, et al.
Published: (2021)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
by: Xuezhi Hao, et al.
Published: (2021)

A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects
by: Akira Utsunomiya, et al.
Published: (2018)

Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body‐size effect
by: Zheyi Hu, et al.
Published: (2024)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
by: Bruno Sangro, et al.
Published: (2023)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
by: John A. Storwick, et al.
Published: (2024)

Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage
by: Bushra Khan, et al.
Published: (2024)

Hyponatremia and Fever in a Patient on Ipilimumab and Nivolumab (Immune Checkpoint Inhibitors): A Case Report
by: Sumit S. Patel MD, et al.
Published: (2021)

Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid
by: Mika M. Tabata, BS, et al.
Published: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
by: Matthew D. Tucker, et al.
Published: (2021)

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis
by: Hang Xu, et al.
Published: (2019)

Urticaria multiforme: A commonly misdiagnosed entity
by: Reena K Sharma, et al.
Published: (2019)

Urticaria multiforme: a case report in an infant
by: Maria Claudia Alves Luce, et al.
Published: (2019)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023)

Um Caso de Urticária Multiforme em Criança
by: Isabele Oliveira Santos, et al.
Published: (2020)

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1
by: Alessandro Morabito
Published: (2024)

Urticaria multiforme in a child with SARS-CoV-2 infection
by: Konrad Zawadka, et al.
Published: (2021)

Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
by: Makoto Fujiwara, et al.
Published: (2023)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022)

Panhypopituitarism induced by ipilimumab
by: Miyu Shiratori, et al.
Published: (2020)

Ipilimumab: Melanoma and beyond
by: Vishal Patel, et al.
Published: (2011)

Use of ipilimumab in the treatment of melanoma
by: Acharya UH, et al.
Published: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
by: Makiko Ban-Hoefen MD, et al.
Published: (2016)

Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report
by: Ryo Takada, et al.
Published: (2024)

Erythema multiforme following application of hair dye
by: Sankha Koley, et al.
Published: (2012)

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes
by: Chen P, et al.
Published: (2018)

Psoriasiform eruption on the face and extremities associated with nivolumab therapy
by: Amit Om, MD, et al.
Published: (2018)